Advertisement
Advertisement
AUPH
Aurinia Pharmaceuticals Inc
13.96
USDSponsored
-0.41
-2.89%
Mar 13, 15:59 UTC -4
Closed
After-Market
14.05
+0.10
+0.68%
AUPH Earnings Reports
Positive Surprise Ratio
AUPH beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$77.59M
/$0.19
Implied change from Q4 25 (Revenue/ EPS)
+0.62%
/-26.92%
Implied change from Q1 25 (Revenue/ EPS)
+24.22%
/+18.75%
Aurinia Pharmaceuticals Inc earnings per share and revenue
On Feb 26, 2026, AUPH reported earnings of 0.26 USD per share (EPS) for Q4 25, beating the estimate of 0.22 USD, resulting in a 17.65% surprise. Revenue reached 77.11 million, compared to an expected 76.34 million, with a 1.01% difference. The market reacted with a -3.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.19 USD, with revenue projected to reach 77.59 million USD, implying an decrease of -26.92% EPS, and increase of 0.62% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.45
Actual
-$0.42
Surprise
+6.77%
Esperion Therapeutics, Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.24
Actual
$0.22
Surprise
-10.46%
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Zevra Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
$0.05
Actual
$0.21
Surprise
+311.76%
SIGA Technologies Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
-Actual
-$0.08
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.19
Actual
$0.30
Surprise
+54.80%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.25
Surprise
+13.49%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.51
Surprise
+37.05%
Champions Oncology, Inc.
Report Date
Mar 12, 2026 For Q3 26
Estimate
$0.09
Actual
-$0.02
Surprise
-121.79%
FAQ
What were Aurinia Pharmaceuticals Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Aurinia Pharmaceuticals Inc reported EPS of $0.26, beating estimates by 17.65%, and revenue of $77.11M, 1.01% above expectations.
How did the market react to Aurinia Pharmaceuticals Inc's Q4 2025 earnings?
The stock price moved down -3.19%, changed from $14.43 before the earnings release to $13.97 the day after.
When is Aurinia Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Aurinia Pharmaceuticals Inc's next earnings report?
Based on 5
analysts, Aurinia Pharmaceuticals Inc is expected to report EPS of $0.19 and revenue of $77.59M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement